Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios
Cemiplimab, a monoclonal antibody directed against programmed death receptor 1 (PD-1), has shown promising results in cutaneous squamous cell carcinoma (cSCC). In a nonrandomized trial where cemiplimab 3 mg/kg was given every 2 weeks for up to 96 weeks, a 44% response rate was noted. This case serie...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-08-01
|
| Series: | Journal of Investigative Medicine High Impact Case Reports |
| Online Access: | https://doi.org/10.1177/23247096221121408 |
| _version_ | 1811188960686243840 |
|---|---|
| author | Komal Akhtar MD Metlapalli Venkata Sravanthi MD Josephine D’Angelo MD Abirami Sivapiragasam MD |
| author_facet | Komal Akhtar MD Metlapalli Venkata Sravanthi MD Josephine D’Angelo MD Abirami Sivapiragasam MD |
| author_sort | Komal Akhtar MD |
| collection | DOAJ |
| description | Cemiplimab, a monoclonal antibody directed against programmed death receptor 1 (PD-1), has shown promising results in cutaneous squamous cell carcinoma (cSCC). In a nonrandomized trial where cemiplimab 3 mg/kg was given every 2 weeks for up to 96 weeks, a 44% response rate was noted. This case series discusses 3 unique scenarios of patients with advanced cSCC treated with cemiplimab. The first case is of an end stage kidney disease (ESKD) patient with failed living donor kidney transplant who had developed recurrent cSCC despite several excisions and topical 5-flurouracil and acitretin therapy. He received 8 cycles of cemiplimab leading to resolution. This case serves as an example of the safety and efficacy of cemiplimab in a complex patient who is a kidney transplant recipient on hemodialysis. The second case describes an elderly gentleman with inoperable cSCC initially treated with radiotherapy who later received 9 cycles of cemiplimab for recurrent metastatic disease with excellent response. This case supports the safe and effective use of cemiplimab in an elderly patient. In the third case, cSCC presented itself as a large fungating mass that would have otherwise necessitated limb amputation and was successfully treated with 18 cycles of cemiplimab. This case highlights the dramatic response to cemiplimab obviating the need for surgical intervention and resulting in limb salvage. |
| first_indexed | 2024-04-11T14:27:25Z |
| format | Article |
| id | doaj.art-a747f478c16149abb339b0dfa940dc55 |
| institution | Directory Open Access Journal |
| issn | 2324-7096 |
| language | English |
| last_indexed | 2024-04-11T14:27:25Z |
| publishDate | 2022-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Investigative Medicine High Impact Case Reports |
| spelling | doaj.art-a747f478c16149abb339b0dfa940dc552022-12-22T04:18:48ZengSAGE PublishingJournal of Investigative Medicine High Impact Case Reports2324-70962022-08-011010.1177/23247096221121408Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique ScenariosKomal Akhtar MD0Metlapalli Venkata Sravanthi MD1Josephine D’Angelo MD2Abirami Sivapiragasam MD3SUNY Upstate Medical University, Syracuse, USASUNY Upstate Medical University, Syracuse, USASUNY Upstate Medical University, Syracuse, USASUNY Upstate Medical University, Syracuse, USACemiplimab, a monoclonal antibody directed against programmed death receptor 1 (PD-1), has shown promising results in cutaneous squamous cell carcinoma (cSCC). In a nonrandomized trial where cemiplimab 3 mg/kg was given every 2 weeks for up to 96 weeks, a 44% response rate was noted. This case series discusses 3 unique scenarios of patients with advanced cSCC treated with cemiplimab. The first case is of an end stage kidney disease (ESKD) patient with failed living donor kidney transplant who had developed recurrent cSCC despite several excisions and topical 5-flurouracil and acitretin therapy. He received 8 cycles of cemiplimab leading to resolution. This case serves as an example of the safety and efficacy of cemiplimab in a complex patient who is a kidney transplant recipient on hemodialysis. The second case describes an elderly gentleman with inoperable cSCC initially treated with radiotherapy who later received 9 cycles of cemiplimab for recurrent metastatic disease with excellent response. This case supports the safe and effective use of cemiplimab in an elderly patient. In the third case, cSCC presented itself as a large fungating mass that would have otherwise necessitated limb amputation and was successfully treated with 18 cycles of cemiplimab. This case highlights the dramatic response to cemiplimab obviating the need for surgical intervention and resulting in limb salvage.https://doi.org/10.1177/23247096221121408 |
| spellingShingle | Komal Akhtar MD Metlapalli Venkata Sravanthi MD Josephine D’Angelo MD Abirami Sivapiragasam MD Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios Journal of Investigative Medicine High Impact Case Reports |
| title | Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios |
| title_full | Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios |
| title_fullStr | Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios |
| title_full_unstemmed | Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios |
| title_short | Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios |
| title_sort | cemiplimab for locally advanced cutaneous squamous cell carcinoma a case series of 3 unique scenarios |
| url | https://doi.org/10.1177/23247096221121408 |
| work_keys_str_mv | AT komalakhtarmd cemiplimabforlocallyadvancedcutaneoussquamouscellcarcinomaacaseseriesof3uniquescenarios AT metlapallivenkatasravanthimd cemiplimabforlocallyadvancedcutaneoussquamouscellcarcinomaacaseseriesof3uniquescenarios AT josephinedangelomd cemiplimabforlocallyadvancedcutaneoussquamouscellcarcinomaacaseseriesof3uniquescenarios AT abiramisivapiragasammd cemiplimabforlocallyadvancedcutaneoussquamouscellcarcinomaacaseseriesof3uniquescenarios |